Daratumumab improves the anti-myeloma effect of newly emerging multidrug therapies

Sathish Gopalakrishnan,1 Daryl Tan1,2 1Department of Hematology, Singapore General Hospital, Singapore, Republic of Singapore; 2Raffles Cancer Center, Raffles Hospital, Singapore, Republic of Singapore Abstract: Although the clinical outcomes of patients with multiple myeloma has improved tremendous...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Gopalakrishnan S, Tan D
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2013
Materias:	Diseases of the blood and blood-forming organs RC633-647.5
Acceso en línea:	https://doaj.org/article/73f7face19004ee9bc6bb0fa042fbaf2
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:73f7face19004ee9bc6bb0fa042fbaf2
record_format	dspace
spelling	oai:doaj.org-article:73f7face19004ee9bc6bb0fa042fbaf22021-12-02T06:15:32ZDaratumumab improves the anti-myeloma effect of newly emerging multidrug therapies1179-9889https://doaj.org/article/73f7face19004ee9bc6bb0fa042fbaf22013-04-01T00:00:00Zhttp://www.dovepress.com/daratumumab-improves-the-anti-myeloma-effect-of-newly-emerging-multidr-a12811https://doaj.org/toc/1179-9889Sathish Gopalakrishnan,1 Daryl Tan1,2 1Department of Hematology, Singapore General Hospital, Singapore, Republic of Singapore; 2Raffles Cancer Center, Raffles Hospital, Singapore, Republic of Singapore Abstract: Although the clinical outcomes of patients with multiple myeloma has improved tremendously with the advent of bortezomib and immunomodulatory drugs like thalidomide and lenalidomide, the disease remains incurable and patients will eventually be resistant to these drugs. Novel non-cross-resistant modalities of treatment are needed. Immunotherapy is potentially a very promising therapeutic modality for further development. Daratumumab is a novel, high-affinity, therapeutic human monoclonal antibody against a unique CD38 epitope. It induces tumor-cell killing through several immunological mechanisms. It has shown a favorable safety profile as monotherapy and significant single-agent activity in relapsed/refractory myeloma. It has also demonstrated strong synergism with lenalidomide and bortezomib. The potential of this agent, together with its pharmacokinetics, mode of action, early efficacy, and safety data will be detailed in this review. Keywords: daratumumab, myeloma, monoclonalGopalakrishnan STan DDove Medical PressarticleDiseases of the blood and blood-forming organsRC633-647.5ENBlood and Lymphatic Cancer: Targets and Therapy, Vol 2013, Iss default, Pp 19-24 (2013)
institution	DOAJ
collection	DOAJ
language	EN
topic	Diseases of the blood and blood-forming organs RC633-647.5
spellingShingle	Diseases of the blood and blood-forming organs RC633-647.5 Gopalakrishnan S Tan D Daratumumab improves the anti-myeloma effect of newly emerging multidrug therapies
description	Sathish Gopalakrishnan,1 Daryl Tan1,2 1Department of Hematology, Singapore General Hospital, Singapore, Republic of Singapore; 2Raffles Cancer Center, Raffles Hospital, Singapore, Republic of Singapore Abstract: Although the clinical outcomes of patients with multiple myeloma has improved tremendously with the advent of bortezomib and immunomodulatory drugs like thalidomide and lenalidomide, the disease remains incurable and patients will eventually be resistant to these drugs. Novel non-cross-resistant modalities of treatment are needed. Immunotherapy is potentially a very promising therapeutic modality for further development. Daratumumab is a novel, high-affinity, therapeutic human monoclonal antibody against a unique CD38 epitope. It induces tumor-cell killing through several immunological mechanisms. It has shown a favorable safety profile as monotherapy and significant single-agent activity in relapsed/refractory myeloma. It has also demonstrated strong synergism with lenalidomide and bortezomib. The potential of this agent, together with its pharmacokinetics, mode of action, early efficacy, and safety data will be detailed in this review. Keywords: daratumumab, myeloma, monoclonal
format	article
author	Gopalakrishnan S Tan D
author_facet	Gopalakrishnan S Tan D
author_sort	Gopalakrishnan S
title	Daratumumab improves the anti-myeloma effect of newly emerging multidrug therapies
title_short	Daratumumab improves the anti-myeloma effect of newly emerging multidrug therapies
title_full	Daratumumab improves the anti-myeloma effect of newly emerging multidrug therapies
title_fullStr	Daratumumab improves the anti-myeloma effect of newly emerging multidrug therapies
title_full_unstemmed	Daratumumab improves the anti-myeloma effect of newly emerging multidrug therapies
title_sort	daratumumab improves the anti-myeloma effect of newly emerging multidrug therapies
publisher	Dove Medical Press
publishDate	2013
url	https://doaj.org/article/73f7face19004ee9bc6bb0fa042fbaf2
work_keys_str_mv	AT gopalakrishnans daratumumabimprovestheantimyelomaeffectofnewlyemergingmultidrugtherapies AT tand daratumumabimprovestheantimyelomaeffectofnewlyemergingmultidrugtherapies
_version_	1718399998385717248

Daratumumab improves the anti-myeloma effect of newly emerging multidrug therapies

Ejemplares similares